LUMIBIRD: REVENUES FOR THE FIRST 9 MONTHS OF 2023: €139.0M (+11%)
24 Octubre 2023 - 10:45AM
LUMIBIRD: REVENUES FOR THE FIRST 9 MONTHS OF 2023: €139.0M (+11%)
Lannion, October 24, 2023 –
5:45pm
REVENUES FOR THE FIRST 9 MONTHS OF 2023: €139.0M
(+11%)
- Continued growth for both
divisions at constant exchange rates
- Strong level of activity
expected in Q4
The LUMIBIRD Group (FR0000038242 -
LBIRD), the European leader for laser technologies, recorded
€139.0m of revenues for the first 9 months of 2023, up 11% and 13%
on a like-for-like basis. Business performance was stable in the
3rd quarter, with a seasonal effect slightly more marked than last
year. Third-quarter sales came to €20.0m for the Photonics division
(+2% and +3% at constant exchange rates) and €21.8m for the Medical
division (+2% and +6% at constant exchange rates). For the 4th
quarter, with a strong order book and production facilities at full
capacity, Lumibird again expects strong sales, with a cautious
target of over 8% organic growth in annual revenues.
Consolidated revenues
(unaudited)
Revenues (€m) |
2023 |
2022 |
Reported change |
Change at constant scope and exchange rates |
First quarter |
40.9 |
38.0 |
+8% |
+9% |
Second quarter |
56.3 |
46.0 |
+22% |
+25% |
Third quarter |
41.8 |
40.9 |
+2% |
+5% |
9 months* |
139.0 |
124.9 |
+11% |
+13% |
of which |
|
|
|
|
Photonics* |
65.9 |
58.2 |
+12% |
+15% |
Medical |
73.0 |
66.7 |
+9.5% |
+12% |
* Including
revenues of Convergent, acquired on 31 August, representing €0.7m
in September.
By Market Segment
Over the first 9 months, the Photonics division
grew by +13% (+15% like-for-like and at constant exchange rates)
compared with the first 9 months of 2022, with €20m in the third
quarter (+2% and +3% like-for-like and at constant exchange
rates).
The Defence/Space segment is up +32% in the
third quarter at €6.9m, on a -like-for-like basis, as the Saab
Group's defence laser rangefinder activities were integrated in May
2022. Over 9 months, it grew by +52% to €23.5m, driven by the laser
rangefinder business, which contributed €8.9m to sales, compared
with €1.2m in the first 9 months of 2022.
After the strong growth in H1, the Lidar segment
recorded a temporary decline in sales in the third quarter (-24% at
€4.1m), although business remains buoyant, with growth of 11% to
€18.3m over the first 9 months.
The Industrial and Scientific activities are
stable in Q3 (+1% at €9.1m), with 9-month sales, down 8% at €23.9m,
still affected by capacity restrictions at the start of the
year.
The Medical division, meanwhile, posted sales of
€21.8m in the 3rd quarter (+2% and +6% at constant exchange rates).
Over 9-months, sales grew by 9% to €73.0m (up 12% at constant
exchange rates). The division's sales are split between diagnostics
(25%) and treatment (75%). This growth was driven by new product
launches in several market segments and marketing authorisations in
new geographical areas.
By Geography
The breakdown of 9 months sales by division and
by geographical area is as follows:
Revenues (€m) |
Photonics |
Chg. |
Medical |
Chg. |
EMEA |
33.5 |
+29% |
23.9 |
+20% |
Americas |
12.7 |
-1% |
20.4 |
-5% |
Asia-Pacific |
15.0 |
+24% |
18.6 |
+11% |
ROW |
4.7 |
-36% |
10.1 |
+19% |
Total |
65.9 |
+13% |
73.0 |
+9% |
Unaudited data
Strong growth in the Photonics division in
Europe (+29%) was driven by France and Sweden. Sales in the United
States (-1%) catching up in the 3rd quarter for some of the delay
caused by the postponement of deliveries to certain industrial
customers in the 1st half of the year.
The Medical division's sales for the first 9
months of the year were similar to those recorded in H1, with
strong growth in Europe (+20%) and the rest of the world (+19%,
mainly Australia), good performances in Asia-Pacific, and sales in
the United States which continue to be adversely affected by
exchange rates and the delayed release of new products. Sales of
these new products should have a favourable impact on business in
the 4th quarter.
With seasonality favouring business at the end
of the year, a strong order book and production facilities at full
capacity, Lumibird once again expects record sales in the 4th
quarter.
The Group can therefore maintain its target for
2023 of organic sales growth of at least 8%, based on the scope at
31 December 2022, and sufficient to confirm its EBITDA ratio target
(excluding Convergent Photonics) of over 20%.
LUMIBIRD is one of the world's leading
specialists in lasers. With 50 years of experience and a mastering
of solid state laser, laser diodes and fiber laser technologies,
the Group designs, manufactures and markets high performance lasers
for scientific (laboratories and universities), industrial
(manufacturing, defense, Lidar sensors) and medical (ophthalmology,
ultrasound diagnostic) markets.
Born from the combination of Keopsys Group with
Quantel in October 2017, LUMIBIRD has more than 1 050
employees and over €191 million of consolidated revenues in
2022 and is present in Europe, America and Asia.
LUMIBIRD shares are listed on the
Euronext Paris B Compartment. FR0000038242 –
LBIRD www.lumibird.comSince
2022, LUMIBIRD is part of Euronext Tech
Leaders
Contacts
LUMIBIRDMarc Le FlohicChairman and CEOTel. +33(0) 1 69 29 17
00info@lumibird.com |
LUMIBIRDSonia RutnamChief Financial and Transformation OfficerTel.
+33(0) 1 69 29 17 00info@lumibird.com |
CalyptusMathieu CalleuxInvestors RelationsTel. +33(0) 1 53 65 37
91lumibird@calyptus.net |
- 231024_Lumibird_CAQ3_2023EN
Quantel (LSE:0FRI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Quantel (LSE:0FRI)
Gráfica de Acción Histórica
De May 2023 a May 2024